阿帕替尼应用于食管癌治疗的研究进展  

Research progress of apatinib in the treatment of esophageal carcinoma

作　　者：王裕嘉 周倩[1] 肖毓[1] 谭榜宪[1,2] Wang Yujia;Zhou Qian;Xiao Yu;Tan Bangxian(North Sichuan Medical College,Nanchong 637000,China;Department of Oncology,Affiliated Hospital of North Sichuan Medical College,Nanchong,637000,China)

机构地区：[1]川北医学院,南充637000 [2]川北医学院附属医院肿瘤科,南充637000

出　　处：《中华转移性肿瘤杂志》2021年第3期243-245,共3页Chinese Journal of Metastatic Cancer

摘　　要：食管癌是我国发病率及死亡率较高的消化道常见恶性肿瘤之一,现阶段以手术、放疗、化疗等综合治疗为主。近年来,抗血管生成治疗在多种实体肿瘤治疗中的应用日益增多,也逐渐成为食管癌综合治疗中的一个新选择。抗血管生成药物——新型口服小分子酪氨酸激酶抑制剂阿帕替尼已在食管癌及多种恶性肿瘤治疗中展现出较好的治疗效果。笔者就阿帕替尼在食管癌治疗中的作用机制及临床应用的研究进展进行综述,旨在加深对该药物在食管癌治疗中抗肿瘤机制和疗效的认知,为今后的基础研究与临床治疗提供依据与参考。Esophageal carcinoma is one of the common malignant tumors of digestive tract with high morbidity and mortality in China.At present,the treatment is mainly based on surgery,radiotherapy,chemotherapy and other comprehensive treatment.In recent years,antiangiogenic therapy has been increasingly used in the treatment of a variety of solid tumors,and has gradually become a new choice in the comprehensive treatment of esophageal carcinoma.Among them,the anti-angiogenic drug,a new oral small molecule tyrosine kinase inhibitor apatinib,has shown a good therapeutic effect in the treatment of esophageal carcinoma and a variety of malignant tumors.This article reviews the research progress of the mechanism of action and clinical application of apatinib in the treatment of esophageal carcinoma,aiming to deepen the cognition of the anti-tumor mechanism and efficacy,and to provide basis and reference for the future basic research and clinical treatment.

关 键 词：阿帕替尼 食管肿瘤/抗血管生成疗法 研究进展 

分 类 号：R73[医药卫生—肿瘤]